TCL Archive In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years October 7, 1977
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004